Artículos originales \ Clinical trial reviews
Cerebral embolic protection device in TAVI after the REFLECT II clinical trial: does it change our strategy?
Instituto Cardiovascular, Hospital Clínico San Carlos, Instituto de Investigación del Hospital Clínico San Carlos (IdISSC), Madrid, Spain
REC Interv Cardiol. 2021;3:55-58
The POPular TAVI trial. Antithrombotic therapy following TAVI: towards a minimalist strategy
Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
REC Interv Cardiol. 2020;2:298-301
ISCHEMIA trial: what is the role of revascularization in patients with chronic coronary syndromes?
aServicio de Cardiología, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
bDepartamento de Medicina, Universidad de Oviedo, Oviedo, Asturias, Spain
cInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Asturias, Spain
REC Interv Cardiol. 2020;2:150-152
Onyx ONE trial: a new option in patients at high risk of bleeding
Servicio de Cardiología, Hospital de Cabueñes, Gijón, Spain
REC Interv Cardiol. 2020;1:55-58
COMPLETE revascularization after STEMI? Sure, go ahead
Servicio de Cardiología, Hospital Universitario La Paz, IdiPaz, Universidad Autónoma de Madrid, CIBER-CV, Madrid, Spain
REC Interv Cardiol. 2019;3:203-206
DinoSAVR struck by the TAVR asteroids
Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
REC Interv Cardiol. 2019;2:131-135
Aspirin-free antithrombotic management following coronary stenting. Myth or reality?
aDivision of Cardiology, CAST, P.O. “Rodolico”, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
bIcahn School of Medicine at Mount Sinai, New York, NY, United States
cDivision of Cardiology, University of Florida College of Medicine, Jacksonville, FL, United States
REC Interv Cardiol. 2019;1:62-66